ABOUT RITUXIMAB

Truqap is really a kinase inhibitor that actually works by blocking pathways that enable the most cancers cells survive and develop, so minimizes most cancers progress. Truqap is from a category of medicines identified as an AKT inhibitor. Truqap acquired FDA acceptance on November 17, 2023, after favourable effects in the CAPItello-291 Section III